Δ133p53/FLp53 Predicts Poor Clinical Outcome in Esophageal Squamous Cell Carcinoma.
esophageal squamous cell carcinoma
p53
prognosis
recurrence
Δ133p53
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
05
2020
accepted:
25
07
2020
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
5
9
2020
Statut:
epublish
Résumé
p53 isoform Δ133p53 is directly transactivated by p53 and antagonizes p53 activities in cancer progression. However, its correlation with prognosis and cancer recurrence in esophageal squamous cell carcinoma (ESCC) is still unclear. Expression of Δ133p53 and Δ133p53/full-length p53 (FLp53) in tissues and serums of 180 ESCC patients was evaluated using qRT-PCR. Patients were divided into high- and low-expression groups according to the cutoff value determined by X-tile 3.6.1 software. Survival analysis was performed by the Kaplan-Meier method. Univariate and multivariate Cox survival analyses were applied to assess the hazard ratios (HRs). Tissue Δ133p53 expression and Δ133p53/FLp53 ratio were significantly increased in ESCC tissue compared with adjacent normal tissue. Pre-operative Δ133p53 expression and Δ133p53/FLp53 ratio in tissue or serum samples were positively associated with TNM stage and post-operative recurrence. Kaplan-Meier curve and multivariate cox regression analyses revealed that the tissue and serum Δ133p53/FLp53 ratios (cutoff value: 2.9160) were independent prognostic factors for overall survival (OS) and progression-free survival (PFS) in ESCC patients and showed no statistical difference in receiver-operating characteristic curve (ROC) analysis, while serum Δ133p53 showed no significant prognostic value. More importantly, the serum Δ133p53/FLp53 ratio in ESCC patients was significantly decreased within 72 h post tumor resection and patients with a consistently high serum Δ133p53/FLp53 ratio (≥2.9160) had higher recurrence rates than those with consistently low ratio values. In addition, dynamic detection in each follow-up timepoint showed that serum Δ133p53/FLp53 ratios were higher than 2.9160 upon recurrence, and they even increased prior to radiologic progression. The serum Δ133p53/FLp53 ratio can be a novel predictor for survival outcome and may serve as a real-time parameter for monitoring recurrence in ESCC patients after surgery.
Sections du résumé
BACKGROUND
BACKGROUND
p53 isoform Δ133p53 is directly transactivated by p53 and antagonizes p53 activities in cancer progression. However, its correlation with prognosis and cancer recurrence in esophageal squamous cell carcinoma (ESCC) is still unclear.
PATIENTS AND METHODS
METHODS
Expression of Δ133p53 and Δ133p53/full-length p53 (FLp53) in tissues and serums of 180 ESCC patients was evaluated using qRT-PCR. Patients were divided into high- and low-expression groups according to the cutoff value determined by X-tile 3.6.1 software. Survival analysis was performed by the Kaplan-Meier method. Univariate and multivariate Cox survival analyses were applied to assess the hazard ratios (HRs).
RESULTS
RESULTS
Tissue Δ133p53 expression and Δ133p53/FLp53 ratio were significantly increased in ESCC tissue compared with adjacent normal tissue. Pre-operative Δ133p53 expression and Δ133p53/FLp53 ratio in tissue or serum samples were positively associated with TNM stage and post-operative recurrence. Kaplan-Meier curve and multivariate cox regression analyses revealed that the tissue and serum Δ133p53/FLp53 ratios (cutoff value: 2.9160) were independent prognostic factors for overall survival (OS) and progression-free survival (PFS) in ESCC patients and showed no statistical difference in receiver-operating characteristic curve (ROC) analysis, while serum Δ133p53 showed no significant prognostic value. More importantly, the serum Δ133p53/FLp53 ratio in ESCC patients was significantly decreased within 72 h post tumor resection and patients with a consistently high serum Δ133p53/FLp53 ratio (≥2.9160) had higher recurrence rates than those with consistently low ratio values. In addition, dynamic detection in each follow-up timepoint showed that serum Δ133p53/FLp53 ratios were higher than 2.9160 upon recurrence, and they even increased prior to radiologic progression.
CONCLUSION
CONCLUSIONS
The serum Δ133p53/FLp53 ratio can be a novel predictor for survival outcome and may serve as a real-time parameter for monitoring recurrence in ESCC patients after surgery.
Identifiants
pubmed: 32884352
doi: 10.2147/CMAR.S263559
pii: 263559
pmc: PMC7443442
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7405-7417Informations de copyright
© 2020 Tu et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest for this work.
Références
Cell Res. 2015 Mar;25(3):351-69
pubmed: 25698579
Br J Cancer. 2011 Nov 8;105(10):1593-9
pubmed: 22009029
Nat Commun. 2017 Aug 11;8:16016
pubmed: 28799539
FASEB J. 2019 Mar;33(3):4225-4235
pubmed: 30540922
Gastroenterology. 2015 Dec;149(7):1700-15
pubmed: 26376349
Cell. 2017 Sep 7;170(6):1062-1078
pubmed: 28886379
Nat Rev Cancer. 2018 Feb;18(2):89-102
pubmed: 29242642
Nat Genet. 2016 Dec;48(12):1500-1507
pubmed: 27749841
Nat Genet. 2014 May;46(5):467-73
pubmed: 24686850
Clin Cancer Res. 2004 Nov 1;10(21):7252-9
pubmed: 15534099
Nature. 2014 May 1;509(7498):91-5
pubmed: 24670651
Nat Commun. 2018 Jan 17;9(1):254
pubmed: 29343721
Nat Cell Biol. 2009 Sep;11(9):1135-42
pubmed: 19701195
Sci Rep. 2016 Nov 22;6:37281
pubmed: 27874035
Clin Cancer Res. 2017 Nov 1;23(21):6487-6497
pubmed: 28760909
Nat Commun. 2017 Nov 16;8(1):1533
pubmed: 29142225
Oncogene. 2013 Apr 25;32(17):2150-60
pubmed: 22733133
Cell Death Dis. 2018 Jul 3;9(7):750
pubmed: 29970881
Elife. 2016 Sep 15;5:
pubmed: 27630122
Sci Rep. 2015 May 18;5:10291
pubmed: 25980316
Cell Death Differ. 2011 Feb;18(2):248-58
pubmed: 20689555
Gastroenterology. 2016 May;150(5):1171-1182
pubmed: 26873401
J Pathol. 2018 Sep;246(1):77-88
pubmed: 29888503
Cancer Discov. 2018 Oct;8(10):1270-1285
pubmed: 30166348
Clin Cancer Res. 2007 May 15;13(10):2992-7
pubmed: 17505001
Nat Genet. 2013 Jun;45(6):632-8
pubmed: 23644492
EBioMedicine. 2018 Jun;32:111-118
pubmed: 29807833
Nat Genet. 2014 Oct;46(10):1097-102
pubmed: 25151357
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
N Engl J Med. 2019 Jan 10;380(2):152-162
pubmed: 30625052
Clin Cancer Res. 2007 Nov 1;13(21):6293-300
pubmed: 17975140
EMBO Rep. 2016 Nov;17(11):1542-1551
pubmed: 27702985
Cell Death Differ. 2011 Dec;18(12):1815-24
pubmed: 21941372
J Clin Oncol. 2006 Apr 10;24(11):1754-60
pubmed: 16505414
Oncogene. 2016 Sep 22;35(38):4981-9
pubmed: 26996665
Stem Cell Reports. 2015 Apr 14;4(4):531-40
pubmed: 25754205
Cancer Manag Res. 2018 Jun 08;10:1449-1459
pubmed: 29922089
Cell Death Differ. 2018 Jun;25(6):1063-1079
pubmed: 29511339